Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Measured human dosimetry of 68Ga-DOTATATE.

Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M.

J Nucl Med. 2013 Jun;54(6):855-60. doi: 10.2967/jnumed.112.114165. Epub 2013 Mar 20.

2.

Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.

Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, Lundqvist H, Sundin A, Lubberink M.

J Nucl Med. 2013 Oct;54(10):1755-9. doi: 10.2967/jnumed.113.120600. Epub 2013 Aug 8.

3.

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.

J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30.

4.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.

J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.

5.

Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.

Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.

J Nucl Med. 2016 May;57(5):708-14. doi: 10.2967/jnumed.115.163865. Epub 2016 Jan 14.

6.

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.

7.

Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.

Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo MÁ, Desco M.

PLoS One. 2014 Nov 4;9(11):e111624. doi: 10.1371/journal.pone.0111624. eCollection 2014.

8.

68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.

Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.

J Nucl Med. 2014 Oct;55(10):1598-604. doi: 10.2967/jnumed.114.144543. Epub 2014 Aug 28.

9.

Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.

Hartmann H, Freudenberg R, Oehme L, Zöphel K, Schottelius M, Wester HJ, Wunderlich G, Kotzerke J, Brogsitter C.

Nuklearmedizin. 2014;53(5):211-6. doi: 10.3413/Nukmed-0667-14-05. Epub 2014 Jul 16.

PMID:
25029274
10.

68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer.

Walker R, Deppen S, Smith G, Shi C, Lehman J, Clanton J, Moore B, Burns R, Grogan EL, Massion PP.

PLoS One. 2017 Feb 9;12(2):e0171301. doi: 10.1371/journal.pone.0171301. eCollection 2017.

11.

68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC.

J Nucl Med. 2016 Jun;57(6):872-8. doi: 10.2967/jnumed.115.165803. Epub 2016 Jan 14. Review.

12.

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP.

Recent Results Cancer Res. 2013;194:519-36. doi: 10.1007/978-3-642-27994-2_30.

PMID:
22918780
13.

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.

Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.

J Nucl Med. 2010 Jun;51(6):875-82. doi: 10.2967/jnumed.109.066134. Epub 2010 May 19.

15.

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB.

J Nucl Med. 2009 Dec;50(12):1927-32. doi: 10.2967/jnumed.109.066639. Epub 2009 Nov 12.

16.

Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.

PMID:
22918768
17.

Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.

Kulkarni HR, Schuchardt C, Baum RP.

Recent Results Cancer Res. 2013;194:551-9. doi: 10.1007/978-3-642-27994-2_32.

PMID:
22918782
18.

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.

Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A.

J Nucl Med. 2012 Aug;53(8):1207-15. doi: 10.2967/jnumed.111.101469. Epub 2012 Jul 10.

19.

Sandostatin LAR therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared to primary tumors and metastatic lesions.

Ayati N, Lee ST, Zakavi SR, Pathmaraj K, Qatawneh L, Poon A, Scott A.

J Nucl Med. 2017 Jul 20. pii: jnumed.117.192203. doi: 10.2967/jnumed.117.192203. [Epub ahead of print]

PMID:
28729431
20.

A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.

Kunikowska J, Pawlak D, Kolasa A, Mikołajczak R, Królicki L.

Clin Nucl Med. 2014 Oct;39(10):855-61. doi: 10.1097/RLU.0000000000000533.

PMID:
25072928

Supplemental Content

Support Center